How big is Selecta Biosciences, Inc.?

As of Jun 18, Selecta Biosciences, Inc. has a market capitalization of 251.85 million, with net sales of 40.78 million and a net profit of -89.08 million over the last four quarters. The company reported shareholder's funds of -6.80 million and total assets of 435.02 million as of Dec 24.

Market Cap: As of Jun 18, Selecta Biosciences, Inc. has a market capitalization of 251.85 million, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Selecta Biosciences, Inc. reported net sales of 40.78 million and a net profit of -89.08 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of -6.80 million and total assets of 435.02 million.

What does Selecta Biosciences, Inc. do?

Selecta Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted immune-modulating therapies for rare diseases. As of March 2025, it reported net sales of $1 million and a net loss of $18 million, with a market cap of $251.85 million.

Overview: <BR>Selecta Biosciences, Inc. is a clinical-stage biopharmaceutical company in the Pharmaceuticals & Biotechnology industry, focusing on developing targeted therapies to modulate the immune system for rare and serious diseases.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 1 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -18 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 251.85 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: 8.11 <BR>Return on Equity: 158.25% <BR>Price to Book: -11.56<BR><BR>Contact Details: <BR>Address: 65 Grove Street, WATERTOWN MA: 02472-2891 <BR>Tel: ['1 617 9231400', '1 646 378-2922'] <BR>Fax: 1 617 9243454 <BR>Website: http://selectabio.com/

Should I buy, sell or hold Selecta Biosciences, Inc.?

Who are in the management team of Selecta Biosciences, Inc.?

As of March 2022, the management team of Selecta Biosciences, Inc. includes Ms. Carrie Cox as Independent Chairman and Dr. Carsten Brunn as President and CEO, along with several Independent Directors on the Board.

As of March 2022, the management team of Selecta Biosciences, Inc. includes:<BR><BR>- Ms. Carrie Cox, who serves as the Independent Chairman of the Board.<BR>- Dr. Carsten Brunn, who is the President, Chief Executive Officer, and a Director.<BR><BR>Additionally, the Board of Directors features several Independent Directors, including Dr. Goran Ando, Mr. Timothy Barabe, Mr. Scott Myers, Mr. Aymeric Sallin, and Mr. Timothy Springer.

Is Selecta Biosciences, Inc. overvalued or undervalued?

As of May 4, 2023, Selecta Biosciences, Inc. is considered overvalued with negative valuation ratios and a year-to-date stock return of -42.43%, significantly underperforming compared to the S&P 500's 12.22% gain.

As of 4 May 2023, Selecta Biosciences, Inc. has moved from a fair to a risky valuation grade. The company appears to be overvalued based on its negative valuation ratios, including a Price to Book Value of -13.03, an EV to EBIT of -2.80, and an EV to EBITDA of -2.85. In comparison to peers, Selecta's P/E ratio stands at -6.4234, while Foghorn Therapeutics, Inc. has a P/E of -4.3113 and Invivyd, Inc. at -2.0534, indicating that Selecta is lagging behind its competitors in terms of valuation metrics.<BR><BR>The company's stock performance has been significantly underwhelming, with a year-to-date return of -42.43% compared to the S&P 500's positive return of 12.22% during the same period. This stark contrast reinforces the notion that Selecta Biosciences, Inc. is currently overvalued given its financial metrics and poor stock performance relative to the broader market.

Is Selecta Biosciences, Inc. technically bullish or bearish?

As of September 3, 2025, Selecta Biosciences, Inc. is in a bearish trend with weak strength, indicated by daily moving averages and On-Balance Volume, despite some mildly bullish signals from weekly indicators, and has significantly underperformed the S&P 500 with a year-to-date return of -42.43%.

As of 3 September 2025, the technical trend for Selecta Biosciences, Inc. has changed from mildly bearish to bearish. The current technical stance is bearish with weak strength, driven by daily moving averages indicating a bearish trend and a bearish outlook from the On-Balance Volume (OBV). While the weekly MACD and KST show mildly bullish signals, they are overshadowed by the overall bearish indicators across other time frames, including Bollinger Bands and Dow Theory. The stock has underperformed significantly compared to the S&P 500, with a year-to-date return of -42.43% versus the S&P 500's 12.22%.